{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:32:22Z","timestamp":1791261142133,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Apart from cessation of the implicated agent leading to drug-induced liver injury (DILI), there is no standard therapy for DILI. Corticosteroids have been used in DILI, although their efficacy is unclear. Published data showed either beneficial effects or no improvement associated with steroid therapy. The aim of the current study was to perform a systematic review of the role of corticosteroids in the treatment of DILI.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A search was performed in PubMed, searching for the terms: \u201ccorticosteroids\u201d and \u201cdrug-induced liver injury\u201d. Observation studies were included, but case reports excluded.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 24 papers were retrieved. Most of these were observational studies on the effects of corticosteroids in moderate\/severe DILI (n = 8), reports on the corticosteroid treatment in patients with drug-induced autoimmune hepatitis (DI-AIH) (n = 5), and effects of corticosteroids in drug-induced fulminant acute liver failure (ALF, n = 2). Furthermore, treatment of corticosteroids in patients with liver injury due to check point inhibitors (CPIs) was addressed in nine studies. In moderate\/severe DILI, six out of eight studies suggested steroid treatment to be beneficial, whereas two studies showed negative results. All five observational studies on the effects of corticosteroids in DI-AIH showed good therapeutic response with rapid and long lasting effects after discontinuation of corticosteroids and without evidence of relapse. Steroid therapy was not associated with improved overall survival in patients with drug-induced fulminant ALF. CPIs-induced liver injury was found to improve spontaneously in 33\u201350% without corticosteroids, and the rate of patients who were treated responded to steroids in 33\u2013100% (mean 72%).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> The majority of studies analyzing the effects of corticosteroids in moderate\/severe DILI have demonstrated beneficial effects. However, this was not the case in drug-induced fulminant ALF. Patients with DI-AIH had an excellent response to corticosteroids. The majority of those with CPIs-induced liver injury responded to corticosteroids; however, patients without treatment usually recovered spontaneously. The observational design and comparison with historical controls in these studies makes it very difficult to draw conclusions on the efficacy of corticosteroids in DILI. Therefore, there is a strong need for a randomized controlled trial to properly assess the role of corticosteroids in DILI.<\/jats:p>","DOI":"10.3389\/fphar.2022.820724","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T10:13:31Z","timestamp":1644488011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Einar S.","family":"Bj\u00f6rnsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Vucic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Stirnimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Robles-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jhep.2007.05.011","article-title":"The Significance of Autoantibodies and Immunoglobulins in Acute Liver Failure: a Cohort Study","volume":"47","author":"Bernal","year":"2007","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/00365520510023846","article-title":"Fulminant Drug-Induced Hepatic Failure Leading to Death or Liver Transplantation in Sweden","volume":"40","author":"Bj\u00f6rnsson","year":"2005","journal-title":"Scand. J. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of Drug-Induced Liver Injury from Tumor Necrosis Factor Antagonists","volume":"13","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug-induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse after Cessation of Steroids","volume":"15","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced Liver Injury: Clinical Phenotypes, Autoimmunity and the Role of Corticosteroid Treatment","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/liv.13538","article-title":"N-acetylcysteine and Prednisolone Treatment Improved Serum Biochemistries in Suspected Flupirtine Cases of Severe Idiosyncratic Liver Injury","volume":"38","author":"Borlak","year":"2018","journal-title":"Liver Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, Clinical Features, and Outcomes from a Prospective Study of Drug-Induced Liver Injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-related Hepatitis: Real-World Experience from a Tertiary centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of Liver Injury Induced by Cancer Immunotherapy Using Immune Checkpoint Inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/gut.20.7.620","article-title":"Randomised Trial of Steroid Therapy in Acute Liver Failure. Report from the European Association for the Study of the Liver (EASL)","volume":"20","year":"1979","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL Clinical Practice Guidelines: Autoimmune Hepatitis","volume":"63","year":"2015","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis Is Associated with Reduced Survival in Patients with Melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"ECR27","DOI":"10.3324\/%25x","article-title":"Corticosteroids Can Reverse Severe Imatinib-Induced Hepatotoxicity","volume":"91","author":"Ferrero","year":"2006","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related Hepatitis with Immunotherapy: Are Corticosteroids Always Needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"101491","DOI":"10.1016\/j.clinre.2020.06.016","article-title":"Severe Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors: Clinical Features and Management Proposal","volume":"45","author":"Gauci","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.23736\/s2724-5985.20.02795-6","article-title":"Drug Induced Liver Injury: from Pathogenesis to Liver Transplantation","volume":"67","author":"Germani","year":"2021","journal-title":"Minerva Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver Injury from Tumor Necrosis Factor-\u03b1 Antagonists: Analysis of Thirty-Four Cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-Induced Liver Injury - Types and Phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12013-012-9373-y","article-title":"Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes","volume":"64","author":"Hou","year":"2012","journal-title":"Cell. Biochem. Biophys."},{"key":"B24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/1751-2980.12383","article-title":"Beneficial Effect of Corticosteroids for Patients with Severe Drug-Induced Liver Injury","volume":"17","author":"Hu","year":"2016","journal-title":"J. Dig. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s12072-021-10238-y","article-title":"Clinical Course of Liver Injury Induced by Immune Checkpoint Inhibitors in Patients with Advanced Malignancies","volume":"15","author":"Ito","year":"2021","journal-title":"Hepatol. Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/hep.26678","article-title":"Steroid Use in Acute Liver Failure","volume":"59","author":"Karkhanis","year":"2014","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late Results of the Royal Free Hospital Prospective Controlled Trial of Prednisolone Therapy in Hepatitis B Surface Antigen Negative Chronic Active Hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/jgh.15041","article-title":"Prevalence, Clinical Course, and Predictive Factors of Immune Checkpoint Inhibitor Monotherapy-Associated Hepatitis in Japan","volume":"35","author":"Kitagataya","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical Characteristics and Adverse Impact of Hepatotoxicity Due to Immune Checkpoint Inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clinre.2017.08.003","article-title":"Features and Outcomes from a Retrospective Study of 570 Hospitalized Chinese Patients with Drug-Induced Liver Injury","volume":"42","author":"Pang","year":"2018","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","article-title":"Incidence of Grade 3-4 Liver Injury under Immune Checkpoints Inhibitors: a Retrospective Study","volume":"69","author":"Parlati","year":"2018","journal-title":"J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of Resuming Anti-PD-1 in Patients with Immune-Related Adverse Events (irAEs) during Combined Anti-CTLA-4 and Anti-PD1 in Metastatic Melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing Toxicities Associated with Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/BF01307513","article-title":"A Double-Blinded, Randomized Trial of Hydrocortisone in Acute Hepatic Failure. The Acute Hepatic Failure Study Group","volume":"36","author":"Rakela","year":"1991","journal-title":"Dig. Dis. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related Hepatitis Related to Checkpoint Inhibitors: Clinical and Prognostic Factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune Hepatitis and Anti-tumor Necrosis Factor Alpha Therapy: A Single center Report of 8 Cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/hep4.1465","article-title":"Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review","volume":"4","author":"Shah","year":"2020","journal-title":"Hepatol. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Autoimmune Acute Liver Failure: Proposed Clinical and Histological Criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The Use of Liver Biopsy Evaluation in Discrimination of Idiopathic Autoimmune Hepatitis versus Drug-Induced Liver Injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e15886","DOI":"10.1097\/MD.0000000000015886","article-title":"Prednisone Is Not Beneficial for the Treatment of Severe Drug-Induced Liver Injury: an Observational Study (STROBE Compliant)","volume":"98","author":"Wan","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B44","first-page":"130","article-title":"A Controlled Trial of Steroid Therapy in Massive Hepatic Necrosis","volume":"62","author":"Ware","year":"1974","journal-title":"Am. J. Gastroenterol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.14195","article-title":"Early ALT Response to Corticosteroid Treatment Distinguishes Idiosyncratic Drug-Induced Liver Injury from Autoimmune Hepatitis","volume":"39","author":"Weber","year":"2019","journal-title":"Liver Int."},{"key":"B46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2796.2007.01818.x","article-title":"Acute Liver Failure in Sweden: Etiology and Outcome","volume":"262","author":"Wei","year":"2007","journal-title":"J. Intern. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000322298","article-title":"Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury","volume":"84","author":"Wree","year":"2011","journal-title":"Digestion"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.820724\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T10:13:36Z","timestamp":1644488016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.820724\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":47,"alternative-id":["10.3389\/fphar.2022.820724"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.820724","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"article-number":"820724"}}